Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.
Cell Differentiation
/ drug effects
Cell Line
Chromosomes, Human, Pair 5
/ drug effects
Core Binding Factor Alpha 2 Subunit
/ genetics
Down-Regulation
/ drug effects
GATA2 Transcription Factor
/ genetics
HEK293 Cells
Humans
Lenalidomide
/ pharmacology
Megakaryocytes
/ drug effects
Mutation
/ drug effects
Myelodysplastic Syndromes
/ genetics
Tumor Suppressor Protein p53
/ genetics
Journal
Nature cell biology
ISSN: 1476-4679
Titre abrégé: Nat Cell Biol
Pays: England
ID NLM: 100890575
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
26
03
2019
accepted:
28
02
2020
pubmed:
7
4
2020
medline:
8
7
2020
entrez:
7
4
2020
Statut:
ppublish
Résumé
Interstitial deletion of the long arm of chromosome 5 (del(5q)) is the most common structural genomic variant in myelodysplastic syndromes (MDS)
Identifiants
pubmed: 32251398
doi: 10.1038/s41556-020-0497-9
pii: 10.1038/s41556-020-0497-9
doi:
Substances chimiques
Core Binding Factor Alpha 2 Subunit
0
GATA2 Transcription Factor
0
Tumor Suppressor Protein p53
0
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
526-533Subventions
Organisme : CIHR
ID : PJT-166051
Pays : Canada
Organisme : CIHR
ID : PJT-162131
Pays : Canada
Références
Bejar, R., Levine, R. & Ebert, B. L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J. Clin. Oncol. 29, 504–515 (2011).
doi: 10.1200/JCO.2010.31.1175
Gohring, G. et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann. Hematol. 89, 365–374 (2010).
doi: 10.1007/s00277-009-0846-z
Talati, C., Sallman, D. & List, A. F. SOHO state of the art and next questions: management of myelodysplastic syndromes with deletion 5q. Clin. Lymphoma Myeloma Leuk. 18, 629–635 (2018).
doi: 10.1016/j.clml.2018.07.293
Kronke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523, 183–188 (2015).
doi: 10.1038/nature14610
Fang, J. et al. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nat. Med. 22, 727–734 (2016).
doi: 10.1038/nm.4127
Jadersten, M. et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J. Clin. Oncol. 29, 1971–1979 (2011).
doi: 10.1200/JCO.2010.31.8576
Scharenberg, C. et al. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica 102, 498–508 (2017).
doi: 10.3324/haematol.2016.152025
Cunningham, L. et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction. Proc. Natl Acad. Sci. USA 109, 14592–14597 (2012).
doi: 10.1073/pnas.1200037109
Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010).
doi: 10.1126/science.1177319
Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771–4779 (2011).
doi: 10.1182/blood-2011-05-356063
Matheny, C. J. et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J. 26, 1163–1175 (2007).
doi: 10.1038/sj.emboj.7601568
Croce, K. et al. Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J. Biol. Chem. 274, 36321–36327 (1999).
doi: 10.1074/jbc.274.51.36321
Sekeres, M. A. et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 26, 5943–5949 (2008).
doi: 10.1200/JCO.2007.15.5770
Yoshida, T., Ng, S. Y., Zuniga-Pflucker, J. C. & Georgopoulos, K. Early hematopoietic lineage restrictions directed by Ikaros. Nat. Immunol. 7, 382–391 (2006).
doi: 10.1038/ni1314
Malinge, S. et al. Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood 121, 2440–2451 (2013).
doi: 10.1182/blood-2012-08-450627
von Palffy, S. et al. Dominant-negative IKAROS enhances IL-3-stimulated signaling in wild-type but not BCR-ABL1
doi: 10.1016/j.exphem.2015.04.004
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
doi: 10.1093/nar/gkw377
Tijssen, M. R. et al. Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev. Cell 20, 597–609 (2011).
doi: 10.1016/j.devcel.2011.04.008
Fink, E. C. et al. Crbn
doi: 10.1182/blood-2018-05-852798
Boultwood, J. et al. Gene expression profiling of CD34
doi: 10.1111/j.1365-2141.2007.06833.x
Graubert, T. A. et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS ONE 4, e4583 (2009).
doi: 10.1371/journal.pone.0004583
Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305–309 (2014).
doi: 10.1126/science.1244917
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
doi: 10.1093/bioinformatics/btp324
Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011).
doi: 10.1038/nature10351
Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
doi: 10.1101/gr.129684.111
Cingolani, P. et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front. Genet. 3, 35 (2012).
doi: 10.3389/fgene.2012.00035
He, J. et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 127, 3004–3014 (2016).
doi: 10.1182/blood-2015-08-664649
Cancer Genome Atlas Research NetworkGenomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
doi: 10.1056/NEJMoa1301689
Griffith, M. et al. Alternative expression analysis by RNA sequencing. Nat. Methods 7, 843–847 (2010).
doi: 10.1038/nmeth.1503
Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26, 873–881 (2010).
doi: 10.1093/bioinformatics/btq057
DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530–1532 (2012).
doi: 10.1093/bioinformatics/bts196
Patro, R., Mount, S. M. & Kingsford, C. Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat. Biotechnol. 32, 462–464 (2014).
doi: 10.1038/nbt.2862
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
doi: 10.1186/s13059-014-0550-8
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
Chacon, D., Beck, D., Perera, D., Wong, J. W. & Pimanda, J. E. BloodChIP: a database of comparative genome-wide transcription factor binding profiles in human blood cells. Nucleic Acids Res. 42, D172–D177 (2014).
doi: 10.1093/nar/gkt1036
Nguyen, T. T. et al. Revealing a human p53 universe. Nucleic Acids Res. 46, 8153–8167 (2018).
doi: 10.1093/nar/gky720